NCT06088888
TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
At risk: Primary completion moved at least 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Mar 30, 2027 to Dec 31, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 40 words
- Primary endpoints: details revised at 1 of 4 entries
- Study completion pushed from Jun 30, 2027 to Feb 29, 2028
- Secondary endpoints: details revised at 3 of 14 entries
- Study title shortened, about 4 words
- Minor Start date changed from estimate of Jun 15, 2024 to Jul 2, 2024v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Mar 15, 2024 to Jun 15, 2024
- Study sites: 1 to 2
- Notable Start date: Jan 30, 2024 to Mar 15, 2024v3
- Notable Start date: Nov 30, 2023 to Jan 30, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Recommended dose for expansion (RDE)
Timeframe: Time Frame: At end of Dose Escalation part of study, an average of 1 year
Safety profile (DLT)
Timeframe: Time Frame: DLT: collect during Cycle 1 (28 days)
Safety profile (AEs/SAEs)
Timeframe: AE and SAE: through completion of the study, an average of 2 years
Recommended phase II dose (RP2D)
Timeframe: At completion of the study, an average of 2 years
Secondary (14)
Hematologic Response
Cytogenetic Response
Molecular Response
Plasma Cmax
Plasma Tmax
Show 9 moreShow less
Plasma T1/2
Plasma AUClast
Plasma AUCinf
Plasma Cmin
Plasma AUCss
Plasma Cmax,ss
Plasma Tmax,ss
CL (Clearance)
Vd (Volume of distribution)
Arms and interventions
TGRX-678Experimental
Subjects to be treated with the investigational drug TGRX-678
Drugs: TGRX-678
Sites
2 sites in 1 country